Concepedia

Su Young Kim

SY

7

Publications

497

Citations

7

H-Index

2005

Active since

Affiliations

AbbVie (United States)(Current)

Peter MacCallum Cancer Centre

St. Jude Children's Research Hospital

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Su Young Kim is an author at AbbVie (United States) specializing in cancer therapeutics, clinical trials, and drug development.

Top concepts

Publications per year

2005–2021

7

Publications

7

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Vinod Pullarkat, Norman J. Lacayo, Elias Jabbour et al. · Cancer Discovery · 2021 · 270 citations · Full text

A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

John F. Gerecitano, Andrew W. Roberts, John F. Seymour et al. · Blood · 2015 · 74 citations

Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies

Andrew E. Place, Kelly C. Goldsmith, Jean‐Pierre Bourquin et al. · Future Oncology · 2018 · 62 citations · Full text

, , +25

Mutational analysis of the <i>ARAF</i> gene in human cancers

Jong Woo Lee, Young Hwa Soung, Su Young Kim et al. · Apmis · 2005 · 47 citations

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · Blood · 2019 · 19 citations

Rows per page

1–5 of 7